Fresenius Q2 Profit Rises, EBIT Down; Backs FY25 EBIT Growth View, Lifts Organic Revenue Forecast

Fresenius SE reported mixed Q2 results, with net income excluding Fresenius Medical Care rising 6% to €412 million on a 3% increase in group revenues to €5.57 billion, driven by 5% organic growth. However, Group EBIT declined 1% to €654 million, and the EBIT margin compressed to 11.7%, impacted by the cessation of energy relief payments in Germany and the loss of a product tender in China. Despite these Q2 pressures, the German healthcare firm raised its fiscal 2025 organic revenue growth forecast to 5-7% from 4-6%, while reaffirming its 3-7% constant currency EBIT growth outlook, signaling strategic confidence despite current margin headwinds.

Analysis

Fresenius SE presented a mixed financial profile in its second-quarter results, characterized by resilient top-line growth juxtaposed with declining profitability. Group revenues increased 3% to €5.57 billion, underpinned by a stronger 5% organic growth rate driven by its core Kabi and Helios segments. This performance, however, did not translate to the bottom line, as Group EBIT fell 1% to €654 million, compressing the EBIT margin to 11.7% from 12.2% a year prior. The company attributed this margin pressure to two specific, non-operational factors: the cessation of energy relief payments in Germany and the loss of a key product tender in China. Despite these immediate headwinds, management signaled strong confidence in its long-term trajectory by raising its fiscal 2025 organic revenue growth guidance to a range of 5% to 7%, up from the previous 4% to 6%. Concurrently, it reaffirmed its fiscal 2025 constant currency EBIT growth forecast of 3% to 7%, implying a belief that current margin pressures can be overcome to meet future profitability targets.

Key Decisions for Investors

• Investors should weigh the upgraded fiscal 2025 revenue guidance as a strong signal of long-term strategic confidence, which may offset concerns regarding the transient nature of the current quarter's margin compression.
• It is crucial to monitor for management commentary on mitigating the specific headwinds that impacted Q2 EBIT, namely the normalized energy cost environment at Helios Germany and the competitive landscape for Fresenius Kabi in China.
• Given the reaffirmed EBIT growth outlook for 2025 despite current pressures, investors should closely track margin performance in upcoming quarters as a key indicator of the company's ability to execute on its #FutureFresenius program and translate top-line growth into profitability.